Table 3: Acute toxicities during TPF and CCRT.
|
|
TPF (n=28) |
CCRT (n=27) |
||||||
|
Toxicity/Grade |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
|
Vomiting |
6 (21.4%) |
2 (7.14%) |
2 (7.14%) |
0 |
3 (11.1%) |
2 (7.41%) |
3 (11.1%) |
0 |
|
Diarrhea |
6 (21.4%) |
2 (7.14%) |
7 (25%) |
0 |
0 |
0 |
0 |
0 |
|
HFS |
1 (3.57%) |
0 |
0 |
0 |
0 |
0 |
1 (3.70%) |
0 |
|
Neutropenia |
1 (3.57%) |
0 |
1 (3.57%) |
2 (7.14%) |
4 (14.8%) |
5 (18.5%) |
7 (25.9%) |
1 (3.70%) |
|
Neutropenic fever |
1 (3.57%) |
0 |
1 (3.57%) |
0 |
2 (7.40%) |
0 |
1 (3.70%) |
0 |
|
Non-neutropenic infection |
0 |
2 (7.14%) |
1 (3.57%) |
0 |
0 |
0 |
2 (7.40%) |
0 |
|
Anaemia |
17 (60.7%) |
6 (21.4%) |
2 (7.14%) |
0 |
10 (37.0%) |
8 (29.6%) |
9 (33.3%) |
0 |
|
Thrombocytopenia |
7 (25%) |
0 |
0 |
0 |
11 (40.7%) |
5 (18.5%) |
0 |
0 |
|
Hearing loss |
0 |
0 |
0 |
0 |
1 (3.70%) |
0 |
0 |
0 |
|
Mucositis |
1 (3.57%) |
0 |
0 |
0 |
2 (7.41%) |
12 (44.4%) |
13 (48.1%) |
0 |
|
Neuropathy |
2 (7.14%) |
0 |
0 |
0 |
0 |
1 (3.70%) |
0 |
0 |
|
Impaired renal function |
9 (32.1%) |
0 |
0 |
0 |
14 (51.9%) |
1 (3.70%) |
0 |
0 |
|
Increased alanine transaminase |
7 (25%) |
1 (3.57%) |
0 |
0 |
2 (7.40%) |
1 (3.70%) |
0 |
0 |
|
Increased bilirubin |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Hypokalaemia |
14 (50%) |
3 (10.7%) |
0 |
0 |
6 (22.2%) |
4 (14.8%) |
0 |
0 |
|
Hyponatremia |
13 (46.4%) |
2 (7.14%) |
2 (7.14%) |
1 (3.57%) |
13 (48.1%) |
0 |
2 (7.41%) |
0 |
|
Skin Reaction |
|
|
|
|
11 (40.7%) |
12 (44.4%) |
3 (11.1%) |
0 |
|
Tube Feeding |
|
|
|
|
3 (11.1%) |
0 |
0 |
0 |
|
Others* |
0 |
0 |
0 |
1 (3.57%)* |
|
|
|
|
CCRT: Concurrent Chemoradiotherapy; HFS: Hand Foot Syndrome; *ST- elevation myocardial infarction. *estimated 3-year OS; §estimated 3-year PFS.